Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Grows By 24.9%

Integra LifeSciences Holdings Co. (NASDAQ:IART) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,610,000 shares, an increase of 24.9% from the March 31st total of 2,090,000 shares. Based on an average trading volume of 725,500 shares, the days-to-cover ratio is currently 3.6 days. Approximately 4.0% of the shares of the company are short sold.

Integra LifeSciences Price Performance

Shares of IART traded down $0.07 during trading hours on Tuesday, reaching $29.17. 650,226 shares of the company’s stock traded hands, compared to its average volume of 702,239. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The firm’s 50 day simple moving average is $35.02 and its 200-day simple moving average is $38.71. The stock has a market cap of $2.29 billion, a PE ratio of 35.14, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12. Integra LifeSciences has a 12 month low of $27.18 and a 12 month high of $56.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the prior year, the firm earned $0.94 EPS. Integra LifeSciences’s quarterly revenue was down .3% on a year-over-year basis. Equities analysts expect that Integra LifeSciences will post 3.19 EPS for the current year.

Wall Street Analyst Weigh In

IART has been the topic of several recent research reports. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a report on Wednesday, April 3rd. Truist Financial reduced their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, JMP Securities decreased their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $44.89.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC lifted its position in Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after buying an additional 415 shares during the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Integra LifeSciences by 123.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the last quarter. Gladius Capital Management LP purchased a new stake in shares of Integra LifeSciences in the 3rd quarter valued at $47,000. Valley National Advisers Inc. bought a new position in shares of Integra LifeSciences during the 1st quarter valued at $63,000. Finally, Covestor Ltd lifted its stake in Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.